Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells: Acute Leukemias

Fibroblast growth factors (FGFs) are important regulators of hematopoiesis and have been implicated in the tumorigenesis of solid tumors. Recent evidence suggests that FGF signaling through FGF receptors (FGFRs) may play a role in the proliferation of subsets of acute myeloid leukemias (AMLs). Howev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2006-06, Vol.20 (6), p.979-986
Hauptverfasser: Karajannis, M A, Vincent, L, DiRenzo, R, Shmelkov, S V, Zhang, F, Feldman, E J, Bohlen, P, Zhu, Z, Sun, H, Kussie, P, Rafii, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 986
container_issue 6
container_start_page 979
container_title Leukemia
container_volume 20
creator Karajannis, M A
Vincent, L
DiRenzo, R
Shmelkov, S V
Zhang, F
Feldman, E J
Bohlen, P
Zhu, Z
Sun, H
Kussie, P
Rafii, S
description Fibroblast growth factors (FGFs) are important regulators of hematopoiesis and have been implicated in the tumorigenesis of solid tumors. Recent evidence suggests that FGF signaling through FGF receptors (FGFRs) may play a role in the proliferation of subsets of acute myeloid leukemias (AMLs). However, the precise mechanism and specific FGF receptors that support leukemic cell growth are not known. We show that FGF-2, through activation of FGFR1 β signaling, promotes survival, proliferation and migration of AML cells. Stimulation of FGFR1 β results in phosphoinositide 3-kinase (PI3-K)/Akt activation and inhibits chemotherapy-induced apoptosis of leukemic cells. Neutralizing FGFR1-specific antibody abrogates the physiologic and chemoprotective effects of FGF-2/FGFR1 β signaling and inhibits tumor growth in mice xenotransplanted with human AML. These data suggest that activation of FGF-2/FGFR1 β supports progression and chemoresistance in subsets of AML. Therefore, FGFR1 targeting may be of therapeutic benefit in subsets of AML.
doi_str_mv 10.1038/sj.leu.2404203
format Article
fullrecord <record><control><sourceid>springer</sourceid><recordid>TN_cdi_springer_journals_10_1038_sj_leu_2404203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1038_sj_leu_2404203</sourcerecordid><originalsourceid>FETCH-springer_journals_10_1038_sj_leu_24042033</originalsourceid><addsrcrecordid>eNqVjz1OxDAQhS0EEuGnpZ4DkKydvw0lQgRqRG9Z3tnEwYkjj7MoNTfiIJwJr9gLUE0x73v6HmN3gmeCF82GhszikuUlL3NenLFElNs6rapKnLOEN802rR_y8pJdEQ2cH591wr4edTAHFYybwO2hfWnfxM83kOkmZc3UwaxC_6lWmL0bXUACWvwhEvYeRtP5P1JNO_BIhoKaNEJwoHuM8R69mlcwMaGXgDCuaJ3ZQfT8wNEo0Ggt3bCLvbKEt6d7zTbt8_vTa0qzjwro5eAWH31ICi6PWyUNMnbI09bi_8QvTX1iRg</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells: Acute Leukemias</title><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Karajannis, M A ; Vincent, L ; DiRenzo, R ; Shmelkov, S V ; Zhang, F ; Feldman, E J ; Bohlen, P ; Zhu, Z ; Sun, H ; Kussie, P ; Rafii, S</creator><creatorcontrib>Karajannis, M A ; Vincent, L ; DiRenzo, R ; Shmelkov, S V ; Zhang, F ; Feldman, E J ; Bohlen, P ; Zhu, Z ; Sun, H ; Kussie, P ; Rafii, S</creatorcontrib><description>Fibroblast growth factors (FGFs) are important regulators of hematopoiesis and have been implicated in the tumorigenesis of solid tumors. Recent evidence suggests that FGF signaling through FGF receptors (FGFRs) may play a role in the proliferation of subsets of acute myeloid leukemias (AMLs). However, the precise mechanism and specific FGF receptors that support leukemic cell growth are not known. We show that FGF-2, through activation of FGFR1 β signaling, promotes survival, proliferation and migration of AML cells. Stimulation of FGFR1 β results in phosphoinositide 3-kinase (PI3-K)/Akt activation and inhibits chemotherapy-induced apoptosis of leukemic cells. Neutralizing FGFR1-specific antibody abrogates the physiologic and chemoprotective effects of FGF-2/FGFR1 β signaling and inhibits tumor growth in mice xenotransplanted with human AML. These data suggest that activation of FGF-2/FGFR1 β supports progression and chemoresistance in subsets of AML. Therefore, FGFR1 targeting may be of therapeutic benefit in subsets of AML.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/sj.leu.2404203</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Cancer Research ; Critical Care Medicine ; Hematology ; Intensive ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Oncology ; original-article</subject><ispartof>Leukemia, 2006-06, Vol.20 (6), p.979-986</ispartof><rights>Springer Nature Limited 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.leu.2404203$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.leu.2404203$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Karajannis, M A</creatorcontrib><creatorcontrib>Vincent, L</creatorcontrib><creatorcontrib>DiRenzo, R</creatorcontrib><creatorcontrib>Shmelkov, S V</creatorcontrib><creatorcontrib>Zhang, F</creatorcontrib><creatorcontrib>Feldman, E J</creatorcontrib><creatorcontrib>Bohlen, P</creatorcontrib><creatorcontrib>Zhu, Z</creatorcontrib><creatorcontrib>Sun, H</creatorcontrib><creatorcontrib>Kussie, P</creatorcontrib><creatorcontrib>Rafii, S</creatorcontrib><title>Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells: Acute Leukemias</title><title>Leukemia</title><addtitle>Leukemia</addtitle><description>Fibroblast growth factors (FGFs) are important regulators of hematopoiesis and have been implicated in the tumorigenesis of solid tumors. Recent evidence suggests that FGF signaling through FGF receptors (FGFRs) may play a role in the proliferation of subsets of acute myeloid leukemias (AMLs). However, the precise mechanism and specific FGF receptors that support leukemic cell growth are not known. We show that FGF-2, through activation of FGFR1 β signaling, promotes survival, proliferation and migration of AML cells. Stimulation of FGFR1 β results in phosphoinositide 3-kinase (PI3-K)/Akt activation and inhibits chemotherapy-induced apoptosis of leukemic cells. Neutralizing FGFR1-specific antibody abrogates the physiologic and chemoprotective effects of FGF-2/FGFR1 β signaling and inhibits tumor growth in mice xenotransplanted with human AML. These data suggest that activation of FGF-2/FGFR1 β supports progression and chemoresistance in subsets of AML. Therefore, FGFR1 targeting may be of therapeutic benefit in subsets of AML.</description><subject>Cancer Research</subject><subject>Critical Care Medicine</subject><subject>Hematology</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>original-article</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVjz1OxDAQhS0EEuGnpZ4DkKydvw0lQgRqRG9Z3tnEwYkjj7MoNTfiIJwJr9gLUE0x73v6HmN3gmeCF82GhszikuUlL3NenLFElNs6rapKnLOEN802rR_y8pJdEQ2cH591wr4edTAHFYybwO2hfWnfxM83kOkmZc3UwaxC_6lWmL0bXUACWvwhEvYeRtP5P1JNO_BIhoKaNEJwoHuM8R69mlcwMaGXgDCuaJ3ZQfT8wNEo0Ggt3bCLvbKEt6d7zTbt8_vTa0qzjwro5eAWH31ICi6PWyUNMnbI09bi_8QvTX1iRg</recordid><startdate>20060601</startdate><enddate>20060601</enddate><creator>Karajannis, M A</creator><creator>Vincent, L</creator><creator>DiRenzo, R</creator><creator>Shmelkov, S V</creator><creator>Zhang, F</creator><creator>Feldman, E J</creator><creator>Bohlen, P</creator><creator>Zhu, Z</creator><creator>Sun, H</creator><creator>Kussie, P</creator><creator>Rafii, S</creator><general>Nature Publishing Group UK</general><scope/></search><sort><creationdate>20060601</creationdate><title>Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells</title><author>Karajannis, M A ; Vincent, L ; DiRenzo, R ; Shmelkov, S V ; Zhang, F ; Feldman, E J ; Bohlen, P ; Zhu, Z ; Sun, H ; Kussie, P ; Rafii, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-springer_journals_10_1038_sj_leu_24042033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Cancer Research</topic><topic>Critical Care Medicine</topic><topic>Hematology</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>original-article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karajannis, M A</creatorcontrib><creatorcontrib>Vincent, L</creatorcontrib><creatorcontrib>DiRenzo, R</creatorcontrib><creatorcontrib>Shmelkov, S V</creatorcontrib><creatorcontrib>Zhang, F</creatorcontrib><creatorcontrib>Feldman, E J</creatorcontrib><creatorcontrib>Bohlen, P</creatorcontrib><creatorcontrib>Zhu, Z</creatorcontrib><creatorcontrib>Sun, H</creatorcontrib><creatorcontrib>Kussie, P</creatorcontrib><creatorcontrib>Rafii, S</creatorcontrib><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karajannis, M A</au><au>Vincent, L</au><au>DiRenzo, R</au><au>Shmelkov, S V</au><au>Zhang, F</au><au>Feldman, E J</au><au>Bohlen, P</au><au>Zhu, Z</au><au>Sun, H</au><au>Kussie, P</au><au>Rafii, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells: Acute Leukemias</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><date>2006-06-01</date><risdate>2006</risdate><volume>20</volume><issue>6</issue><spage>979</spage><epage>986</epage><pages>979-986</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><abstract>Fibroblast growth factors (FGFs) are important regulators of hematopoiesis and have been implicated in the tumorigenesis of solid tumors. Recent evidence suggests that FGF signaling through FGF receptors (FGFRs) may play a role in the proliferation of subsets of acute myeloid leukemias (AMLs). However, the precise mechanism and specific FGF receptors that support leukemic cell growth are not known. We show that FGF-2, through activation of FGFR1 β signaling, promotes survival, proliferation and migration of AML cells. Stimulation of FGFR1 β results in phosphoinositide 3-kinase (PI3-K)/Akt activation and inhibits chemotherapy-induced apoptosis of leukemic cells. Neutralizing FGFR1-specific antibody abrogates the physiologic and chemoprotective effects of FGF-2/FGFR1 β signaling and inhibits tumor growth in mice xenotransplanted with human AML. These data suggest that activation of FGF-2/FGFR1 β supports progression and chemoresistance in subsets of AML. Therefore, FGFR1 targeting may be of therapeutic benefit in subsets of AML.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/sj.leu.2404203</doi></addata></record>
fulltext fulltext
identifier ISSN: 0887-6924
ispartof Leukemia, 2006-06, Vol.20 (6), p.979-986
issn 0887-6924
1476-5551
language eng
recordid cdi_springer_journals_10_1038_sj_leu_2404203
source Springer Nature - Complete Springer Journals; Nature; EZB-FREE-00999 freely available EZB journals
subjects Cancer Research
Critical Care Medicine
Hematology
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Oncology
original-article
title Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells: Acute Leukemias
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A06%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-springer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20FGFR1%CE%B2%20signaling%20pathway%20promotes%20survival,%20migration%20and%20resistance%20to%20chemotherapy%20in%20acute%20myeloid%20leukemia%20cells:%20Acute%20Leukemias&rft.jtitle=Leukemia&rft.au=Karajannis,%20M%20A&rft.date=2006-06-01&rft.volume=20&rft.issue=6&rft.spage=979&rft.epage=986&rft.pages=979-986&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/sj.leu.2404203&rft_dat=%3Cspringer%3E10_1038_sj_leu_2404203%3C/springer%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true